Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 840

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

Palumbo, A, Rajkumar, S V, Dimopoulos, M A, Richardson, P G, San Miguel, J, Barlogie, B, Harousseau, J, Zonder, J A, Cavo, M, Zangari, M, Attal, M, Belch, A, Knop, S, Joshua, D, Sezer, O, Ludwig, H, Vesole, D, Bladé, J, Kyle, R, Westin, J, Weber, D, Bringhen, S, Niesvizky, R, Waage, A, von Lilienfeld-Toal, M, Lonial, S, Morgan, G J, Orlowski, R Z, Shimizu, K, Anderson, K C, Boccadoro, M, Durie, B G, Sonneveld, P, Hussein, M A, on behalf of the International Myeloma Working Group·2008·Leukemia
DOI 10.1038/sj.leu.2405062
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.leu.2405062

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 91

  1. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ . Trends in the incidence of deep vein thrombosis and pulmonary embolism. A 25-year population-based study. Arch Intern Med 1998; 158: 585–593. · DOI · Paper page
  2. Sallah S, Wan JY, Nguyen NP . Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002; 87: 575–579. · DOI · Paper page
  3. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ . Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 1999; 159: 445–453. · DOI · Paper page
  4. Samama MM . An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000; 160: 3415–3420. · DOI · Paper page
  5. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ . Risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 2000; 160: 809–815. · DOI · Paper page
  6. Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 2002; 162: 1245–1248. · DOI · Paper page
  7. Ageno W, Squizzato A, Garcia D, Imberti D . Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost 2006; 32: 651–658. · doi:10.1055/s-2006-951293
  8. Bauer KA . The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 2001; 135: 367–373. · DOI · Paper page
  9. Bick RL . Cancer-associated thrombosis. N Engl J Med 2003; 349: 109–111. · doi:10.1056/nejmp030086
  10. Prandoni P, Falanga A, Piccioli A . Cancer and venous thromboembolism. Lancet Oncol 2005; 6: 401–410. · DOI · Paper page
  11. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with mode-negative breast cancer who have estrogenreceptor-positive tumors. N Engl J Med 1989; 320: 479–484. · DOI · Paper page
  12. Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor positive breast cancer. J Natl Cancer Inst 1997; 89: 1673–1682. · DOI · Paper page
  13. White RH, Zhou H, Romano PS . Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003; 90: 446–455. · DOI · Paper page
  14. Bona RD . Thrombotic complications of central venous catheters in cancer patients. Semin Thromb Haemost 1999; 25: 147–155. · DOI
  15. Bern MM, Lokich JJ, Wallach SR, Bothe Jr A, Benotti PN, Arkin CF et al. Very low doses of warfarin can prevent thrombosis in central venous catheters: a randomized prospective trial. Ann Intern Med 1990; 112: 423–428. · DOI · Paper page
  16. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75: 251–253. · DOI · Paper page
  17. Verso M, Agnelli G . Venous thromboembolism associated with long term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21: 3665–3675. · DOI · Paper page
  18. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071–2084. · DOI · Paper page
  19. Sallah S, Husain A, Wan J, Vos P, Nguyen NP . The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol 2004; 15: 1490–1494. · DOI
  20. Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA . Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 2004; 101: 558–566. · DOI · Paper page
  21. Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825–831. · DOI · Paper page
  22. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomized trial. Lancet 2007; 370: 1209–1218. · DOI · Paper page
  23. Zangari M, Saghafifar F, Mehta P, Barlogie B, Fink L, Tricot G . The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 2003; 29: 275–282. · doi:10.1055/s-2003-40965
  24. Fox EA, Kahn SR . The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost 2005; 94: 362–365. · DOI · Paper page
  25. Auwerda JJA, Sonneveld P, de Maat MPM, Leebeek FWG . Prothromboic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica 2007; 92: 279–280. · DOI
  26. Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775–779. · DOI · Paper page
  27. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R . Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16–19. · DOI · Paper page
  28. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492–494. · DOI · Paper page
  29. Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002; 8: 3377–3382.
  30. Schey SA, Cavenagh J, Johnson R, Child JA, Oakervee H, Jones RW . An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk Res 2003; 27: 909–914. · DOI
  31. Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89: 826–831.
  32. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319–4323. · DOI · Paper page
  33. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R . Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003; 121: 768–771. · DOI · Paper page
  34. Palumbo A, Bertola A, Falco P, Rosato R, Cavallo F, Giaccone L et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004; 5: 318–324. · DOI
  35. Dimopoulos MA, Anagnostopoulos A, Terpos E, Repoussis P, Zomas A, Katodritou E et al. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica 2006; 91: 252–254.
  36. Offidani M, Corvatta L, Marconi M, Olivieri A, Catarini M, Mele A et al. Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. Hematol J 2004; 5: 312–317. · DOI
  37. Osman K, Comenzo R, Rajkumar SV . Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001; 344: 1951. · DOI · Paper page
  38. Schutt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Poser M et al. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. Eur J Haematol 2005; 74: 40–46. · DOI
  39. Zervas K, Dimopoulos MA, Hatzicharissi E, Anagnostopoulos A, Papaioannou M, Mitsouli Ch et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann Oncol 2004; 15: 134–138. · DOI
  40. Baz R, Li L, Kottke-Marchant K, Srkalovic G, McGowan B, Yiannaki E et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc 2005; 80: 1568–1574. · DOI · Paper page
  41. Sidra G, Williams CD, Russell NH, Zaman S, Myers B, Byrne JL . Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica 2006; 91: 862–863.
  42. Wu P, Davies FE, Horton C, Jenner MW, Krishnan B, Alvares CL et al. The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide–vincristine–doxorubicin–methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leuk Lymphoma 2006; 47: 2335–2338. · DOI
  43. Dimopoulos MA, Hamilos G, Zomas A, Gika D, Efstathiou E, Grigoraki V et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 2004; 5: 112–117. · DOI
  44. Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM, Polo-Zarzuela M, Sureda A, Barrenetxea C et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004; 18: 856–863. · DOI · Paper page
  45. Kropff MH, Lang N, Bisping G, Dominé N, Innig G, Hentrich M et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 2003; 122: 607–616. · DOI
  46. Suvannasankha A, Fausel C, Juliar BE, Yiannoutsos CT, Fisher WB, Ansari RH et al. Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: a Hoosier Oncology Group Trial, HEM01-21. Oncologist 2007; 12: 99–106. · doi:10.1634/theoncologist.12-1-99
  47. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021–1030. · DOI · Paper page
  48. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100: 1168–1171. · DOI · Paper page
  49. Lee C-K, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol 2003; 21: 2732–2739. · DOI · Paper page
  50. Zonder JA . Thrombotic complications of myeloma therapy. Hematology Am Soc Hematol Educ Program 2006; 1: 348–355. · DOI
  51. Zangari M, Tricot G, Zeldis J, Eddlemon P, Saghafifar F, Barlogie B . Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy. Blood 2001; 98: 775a (abstract [3226]). · DOI · Paper page
  52. Zonder JA, Barlogie B, Durie BG, McCoy J, Crowley J, Hussein MA . Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 2006; 108: 403. · DOI
  53. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2007; 25: 447s (abstract [8025]). · DOI
  54. Dimopoulos MA, Spencer A, Attal M, Prince M, Harousseau J, Dmoszynska A et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): results of a phase 3 study (MM-010). Blood 2005; 106: 6a (abstract [6]). · DOI
  55. Weber D, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer E et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III study (MM-009). J Clin Oncol 2006; 24: 427s (abstract [7521]).
  56. Morgan GJ, Schey SA, Wu P, Srikanth M, Phekoo KJ, Jenner M et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 2007; 137: 268–269. · DOI
  57. Richardson P, Schlossman R, Munshi N, Avigan D, Jagannath S, Alsina M et al. A phase 1 trial of lenalidomide (REVLIMID(R)) with bortezomib (VELCADE(R)) in relapsed and refractory multiple myeloma. Blood 2005; 106: 110a (abstract [365]).
  58. Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma 2003; 4: 32–35. · DOI
  59. Galli M, Elice F, Crippa C, Comotti B, Rodeghiero F, Barbui T . Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. Haematologica 2004; 89: 1141–1142.
  60. Knight R, DeLap RJ, Zeldis JB . Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006; 354: 2079–2080. · DOI · Paper page
  61. Cohen AT, Alikhan R, Arcelus JI, Bergmann JF, Haas S, Merli GJ et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 2005; 94: 750–759. · DOI · Paper page
  62. Haas SK . Venous thromboembolic risk and its prevention in hospitalized medical patients. Semin Thromb Hemost 2002; 28: 577–584. · doi:10.1055/s-2002-36702
  63. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA . Meta-anlaysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007; 146: 278–288. · DOI · Paper page
  64. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999; 341: 793–800. · DOI · Paper page
  65. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874–879. · DOI · Paper page
  66. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. BMJ 2006; 332: 325–329. · DOI · Paper page
  67. Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsart D et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomized clinical trials. Thromb Haemost 2000; 83: 14–19. · DOI
  68. Francis CW . Prophylaxis for thromboembolism in hospitalized medical patients. N Engl J Med 2007; 356: 1438–1444. · DOI · Paper page
  69. Geerts WH, Pineo GF, Heit JA, Berggvist D, Lassen MR, Colwell CW et al. Prevention of venous thromboembolism: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 338–400. · DOI · Paper page
  70. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: III. reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ 1994; 308: 235–246. · DOI · Paper page
  71. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295–1302. · DOI · Paper page
  72. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003; 12: 341–346. · DOI · Paper page
  73. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A et al. Double-bind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886–889. · DOI · Paper page
  74. Taube J, Halsall D, Baglin T . Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816–1819. · DOI · Paper page
  75. Wang M, Weber D, Delasalle K, Alexanian R . Thalidomide–dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol 2005; 79: 194–197. · DOI
  76. Minnema MC, Breitkreutz I, Auwerda JJ, van der Holt B, Cremer FW, van Marion AM et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004; 18: 2044–2046. · doi:10.1038/sj.leu.2403533
  77. Offidani M, Corvetta L, Piersantelli MN, Visani G, Alesiani F, Brunori M et al. Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood 2006; 108: 2159–2164. · DOI
  78. Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004; 126: 715–721. · DOI · Paper page
  79. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050–4053. · DOI · Paper page
  80. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma. J Clin Oncol 2007; 25: 4459–4465. · DOI · Paper page
  81. Baz R, Walker E, Karam MA, Choueiri TK, Jawde RA, Bruening K et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006; 17: 1766–1771. · DOI
  82. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C . Low-dose aspirin for the prevention for atherothrombosis. N Engl J Med 2005; 353: 2373–2383. · DOI · Paper page
  83. Zangari M, Barlogie B, Lee CK, Tricot AE, Fassas A, Anaissie E et al. Protective effect of VELCADE® on thalidomide-associated deep vein thrombosis (DVT). Blood 2004; 104: 13a (abstract [4914]). · doi:10.1182/blood.v104.11.13.13
  84. Cestac P, Bagheri H, Lapeyre-Mestre M, Sie P, Fouladi A, Maupas E et al. Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients. Drug Saf 2003; 26: 197–207. · doi:10.2165/00002018-200326030-00005
  85. Nagge J, Crowther M, Hirsh J . Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 2002; 162: 2605–2609. · doi:10.1001/archinte.162.22.2605
  86. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992; 305: 567–574. · DOI · Paper page
  87. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P . Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl 3): 483S–512S. · DOI · Paper page
  88. Lagerstedt CI, Olsson CB, Fagher BO, Oqvist BW, Albrechtsson U . Need for long term anticoagulant treatment in patients with symptomatic calf-vein thrombosis. Lancet 1985; 2: 515–518. · DOI · Paper page
  89. Moser KM, Fedullo PF, LittleJohn JK, Crawford R . Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. JAMA 1994; 271: 223–225. · doi:10.1001/jama.1994.03510270069042
  90. Bozlar U, Gaughen JR, Nambiar AP, Hagspiel KD . Imaging diagnosis of acute pulmonary embolism. Expert Rev Cardiovasc Ther 2007; 5: 519–529. · DOI
  91. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Martin Prins MB et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146–153. · DOI · Paper page

Cited by

See all 840

Metadata

Authors
Palumbo, A., Rajkumar, S. V., Dimopoulos, M. A., Richardson, P. G., San Miguel, J., Barlogie, B., Harousseau, J., Zonder, J. A., Cavo, M., Zangari, M., Attal, M., Belch, A., Knop, S., Joshua, D., Sezer, O., Ludwig, H., Vesole, D., Bladé, J., Kyle, R., Westin, J., Weber, D., Bringhen, S., Niesvizky, R., Waage, A., von Lilienfeld-Toal, M., Lonial, S., Morgan, G. J., Orlowski, R. Z., Shimizu, K., Anderson, K. C., Boccadoro, M., Durie, B. G., Sonneveld, P., Hussein, M. A., & on behalf of the International Myeloma Working Group
Venue
Leukemia
Publisher
Springer Science and Business Media LLC
Published
2007-12-20
Volume
22
Issue
2
Pages
414-423
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
DOI
10.1038/sj.leu.2405062
OpenAlex
W2097331346
Cited by
840
References
6
FWCI
34.84
Type
journal article
Language
en
Open access
closed
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. https://app.cochat.ai/papers/10.1038/sj.leu.2405062
The paper
Palumbo, A., Rajkumar, S. V., Dimopoulos, M. A., Richardson, P. G., San Miguel, J., Barlogie, B., Harousseau, J., Zonder, J. A., Cavo, M., Zangari, M., Attal, M., Belch, A., Knop, S., Joshua, D., Sezer, O., Ludwig, H., Vesole, D., Bladé, J., Kyle, R., . . . on behalf of the International Myeloma Working Group. (2008). Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. https://doi.org/10.1038/sj.leu.2405062

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.